DelMar Pharma

DMPI NASDAQ
2.250
-0.540
-19.35%
Closed 16:18 05/23 EDT
Open
2.700
Prev Close
2.790
High
2.777
Low
2.220
Volume
209.01K
Avg Vol (3M)
62.72K
52 Week High
9.80
52 Week Low
1.870
% Turnover
8.17%
Market Cap
5.76M
1D
5D
1M
3M
1Y
5Y

Comments

No Data

Company Profile

DelMar Pharmaceuticals, Inc. is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer. VAL-083 is being evaluated in a Phase II clinical trial for the treatment of refractory GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Its drug discovery research focuses on identifying validated clinical and commercial-stage compounds, and establishing a scientific rationale for development in orphan drug indications. VAL-083 is an alkylating agent, which crosses the blood-brain-barrier (BBB).
MORE >

Recently

Name
Price
%Change